Amgen Inc. Increase (Decrease) in Accrued Liabilities
Amgen Inc. (AMGN) reported Increase (Decrease) in Accrued Liabilities of -$58.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-05
- Amgen Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $901.00M, a 9.34% increase year-over-year.
- Amgen Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$959.00M.
- Amgen Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $749.00M, a 2.88% increase year-over-year.
- Amgen Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was -$200.00M.
- Amgen Inc. increase (decrease) in accrued liabilities for fiscal 2025 was $499.00M, a 442.39% increase from fiscal 2024.
- Amgen Inc. increase (decrease) in accrued liabilities for fiscal 2024 was $92.00M, a 90.35% decline from fiscal 2023.
- Amgen Inc. increase (decrease) in accrued liabilities for fiscal 2023 was $953.00M, a 882.47% increase from fiscal 2022.
- Amgen Inc. increase (decrease) in accrued liabilities for fiscal 2022 was $97.00M.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $901.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$58.00M 10-Q · filed 2026-08-05 | $691.00M derived: sum of 3 quarters · filed 2026-08-05 | $491.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$959.00M 10-Q · filed 2026-05-01 | -$210.00M derived: sum of 2 quarters · filed 2026-05-01 | -$410.00M derived: sum of 3 quarters · filed 2026-05-01 | $414.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $749.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $549.00M derived: sum of 2 quarters · filed 2026-02-13 | $1.37B derived: sum of 3 quarters · filed 2026-08-05 | $499.00M 10-K · filed 2026-02-13 |
| 2025-09-30 | -$200.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $624.00M derived: sum of 2 quarters · filed 2026-08-05 | -$250.00M 10-Q · filed 2025-11-05 | $478.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $824.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$50.00M 10-Q · filed 2026-08-05 | $678.00M derived: sum of 3 quarters · filed 2026-08-05 | $403.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$874.00M 10-Q · filed 2026-05-01 | -$146.00M derived: sum of 2 quarters · filed 2026-05-01 | -$421.00M derived: sum of 3 quarters · filed 2026-05-01 | $272.00M derived: sum of 4 quarters · filed 2026-05-01 |
| 2024-12-31 | $728.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $453.00M derived: sum of 2 quarters · filed 2026-02-13 | $1.15B derived: sum of 3 quarters · filed 2026-02-13 | $92.00M 10-K · filed 2026-02-13 |
| 2024-09-30 | -$275.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $418.00M derived: sum of 2 quarters · filed 2025-11-05 | -$636.00M 10-Q · filed 2025-11-05 | $248.00M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-06-30 | $693.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$361.00M 10-Q · filed 2025-08-06 | $523.00M derived: sum of 3 quarters · filed 2026-02-13 | $241.00M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-03-31 | -$1.05B 10-Q · filed 2025-05-02 | -$170.00M derived: sum of 2 quarters · filed 2026-02-13 | -$452.00M derived: sum of 3 quarters · filed 2026-02-13 | $129.00M derived: sum of 4 quarters · filed 2026-02-13 |
| 2023-12-31 | $884.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $602.00M derived: sum of 2 quarters · filed 2026-02-13 | $1.18B derived: sum of 3 quarters · filed 2026-02-13 | $953.00M 10-K · filed 2026-02-13 |
| 2023-09-30 | -$282.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $299.00M derived: sum of 2 quarters · filed 2024-10-31 | $69.00M 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $581.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $351.00M 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | -$230.00M 10-Q · filed 2024-05-03 | |||
| 2022-12-31 | $97.00M 10-K · filed 2025-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |